11th week of 2011 patent applcation highlights part 45 |
Patent application number | Title | Published |
20110065678 | ISOXAZOLIDINE DERIVATIVES - Novel glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds. | 2011-03-17 |
20110065679 | Substituted Porphyrins - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 2011-03-17 |
20110065680 | Metal Complexes - A method for synthesizing a complex having the formula: [L3MO3]″ wherein L | 2011-03-17 |
20110065681 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF - Compounds are provided according to formula 1: | 2011-03-17 |
20110065682 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. | 2011-03-17 |
20110065683 | TRISUBSTITUTED PYRAZOLES AS ACETYLCHOLINE RECEPTOR MODULATORS - The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). | 2011-03-17 |
20110065684 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2011-03-17 |
20110065685 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS - The present invention provides novel compounds of Formula (I) | 2011-03-17 |
20110065686 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES - Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses. | 2011-03-17 |
20110065687 | HYDRAZIDE COMPOUNDS AND USES THEREOF - This application relates to certain novel polycyclic compounds that interact with quadruplex-forming regions of polynucleotides and thereby inhibit translation of genetic information into polypeptides. These compounds can thus provide anticancer and antibacterial and antiviral effects. The invention includes novel compounds and pharmaceutical compositions, and methods of using them to treat cancer and other conditions. | 2011-03-17 |
20110065688 | THERAPEUTIC PIPERAZINES - The invention includes a compound of formula I: | 2011-03-17 |
20110065689 | THERAPEUTIC PIPERAZINES - The invention includes a compound of formula I: | 2011-03-17 |
20110065690 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA - The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions. | 2011-03-17 |
20110065691 | THERAPEUTIC PIPERAZINES - The invention includes a compound of formula I: | 2011-03-17 |
20110065692 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 2011-03-17 |
20110065693 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 2011-03-17 |
20110065694 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof - Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein. | 2011-03-17 |
20110065695 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES - This invention relates to compounds of formula I, | 2011-03-17 |
20110065696 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF - A compound represented by the formula (I): | 2011-03-17 |
20110065697 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY - The use of a compound comprising formula (I): | 2011-03-17 |
20110065698 | NOVEL PROTEIN KINASE MODULATORS - The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules. | 2011-03-17 |
20110065699 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2011-03-17 |
20110065700 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2011-03-17 |
20110065701 | PHARMACEUTICAL COMPOUNDS - A thienopyrimidine of formula (I): | 2011-03-17 |
20110065702 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER - The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof. | 2011-03-17 |
20110065703 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS - The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca | 2011-03-17 |
20110065704 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR - The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders. | 2011-03-17 |
20110065705 | Compositions and Methods of Treating Cell Proliferation Disorders - The invention relates to compounds and methods for treating cell proliferation disorders. | 2011-03-17 |
20110065706 | Therapeutic Agents 812 - A compound of formula I | 2011-03-17 |
20110065707 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES - The present invention relates to compounds of formula (I) | 2011-03-17 |
20110065708 | HETEROCYCLIC OXIME COMPOUNDS - The invention relates to compounds of formula (I) and salts thereof: | 2011-03-17 |
20110065709 | AURORA KINASE MODULATORS AND METHOD OF USE - The present invention relates to chemical compounds having a general formula I | 2011-03-17 |
20110065710 | Insecticidal N-(Heteroarylalkyl)Alkanediamine Derivatives - Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, R | 2011-03-17 |
20110065711 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES - This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA | 2011-03-17 |
20110065712 | TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF - The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders. | 2011-03-17 |
20110065713 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors - The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved. | 2011-03-17 |
20110065714 | SUBSTITUTED QUINAZOLINES - This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim | 2011-03-17 |
20110065715 | Nogo Receptor Binding Small Molecules to Promote Axonal Growth - The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the interaction of Nogo and Nogo receptor (NgR), the use of such compounds and compositions in the treatment or amelioration of conditions diseases or disorders, such as spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, ALS, Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, Schizophrenia or schizoaffective disorders. | 2011-03-17 |
20110065716 | HYDROXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer. | 2011-03-17 |
20110065717 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS - The present invention relates to novel substituted sulfoximine derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 2011-03-17 |
20110065718 | Antifungal Product, Use and Formulation Thereof - An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the C | 2011-03-17 |
20110065719 | PHARMACEUTICAL FORMULATIONS CONTAINING FLAVOURING SUBSTANCES WITH IMPROVED PHARMACEUTICAL - The invention relates to flavouring-containing pharmaceutical formulations with improved pharmaceutical properties, and to process for the production thereof. | 2011-03-17 |
20110065720 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES - The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders. | 2011-03-17 |
20110065721 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE - Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, and adjusting administration to the patient of metaxalone or the substance to avoid an adverse event associated with metaxalone. In another embodiment, the method comprises informing a user that metaxalone is metabolized by a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product. | 2011-03-17 |
20110065722 | A CRYSTALLINE FORM OF POSACONAZOLE - The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections. | 2011-03-17 |
20110065723 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL)AC- ETYL]AMINO]-N-[3-(4-PYRIDYL)-1-[2-(4-PYRIDYL)ETHYL]PROPYL]PROPANAMIDE AND USES THEREOF - The present invention relates to compositions of N-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-N-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide (Timcodar) useful for the treatment of patients with mycobacterium infections such as | 2011-03-17 |
20110065724 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2011-03-17 |
20110065725 | TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY - The invention relates to triazole amide derivatives of formula (I) for use in therapy, in particular for treating diseases and conditions mediated by antagonism of the mGluR | 2011-03-17 |
20110065726 | Organic Compounds - The present invention is directed to a compound of the formula: | 2011-03-17 |
20110065727 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2011-03-17 |
20110065728 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES - The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: | 2011-03-17 |
20110065729 | METHODS AND COMPOSITIONS FOR AMELIORATING THE UNDESIRABLE EFFECTS OF CHEMOTHERAPY - In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at least one adverse effect of chemotherapy, the methods each comprising the step of administering to a subject undergoing chemotherapy an amount of a chemoprotectant composition that is effective to ameliorate at least one adverse effect of the chemotherapy. | 2011-03-17 |
20110065730 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES - The invention relates to novel 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory. | 2011-03-17 |
20110065731 | USES OF DPP-IV INHIBITORS - The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments. | 2011-03-17 |
20110065732 | KIT FOR TOPICAL APPLICATION OF MEDICATION - The application describes a convenient portable kit for the application of topical medications. The kit can be used, for example, as a convenient system for application of cold sore medication. The kit includes a container for a quantity of fluid medication sufficient for several treatments together with a plurality of applicators for said medicine. The applicators are specially designed to apply the medicine accurately and with minimal pain. | 2011-03-17 |
20110065733 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 2011-03-17 |
20110065734 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES - The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth. | 2011-03-17 |
20110065735 | SUBSTITUTED QUINAZOLINES - This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim | 2011-03-17 |
20110065736 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS - The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R | 2011-03-17 |
20110065737 | HCV PROTEASE INHIBITORS - This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection. | 2011-03-17 |
20110065738 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF - The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease. | 2011-03-17 |
20110065739 | NOVEL ISOXAZOLE DRIVATIVE - Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an agonistic activity on GPR120 and is therefore useful for the treatment of diabetes, obesity or hyperlipemia. [In formula (I), the A represents a phenyl group which may be substituted by a lower alkoxy group or the like; the 13 represents a bivalent group produced by removing two hydrogen atoms from a benzene ring which may be substituted by a halogen atom or the like; X represents a lower alkylene group having 2 to 4 carbon atoms in its main chain or the like, wherein a carbon atom constituting the main chain may be substituted by an oxygen atom or the like; and Y represents a hydrogen atom or the like.] | 2011-03-17 |
20110065740 | METHODS OF TREATING TRAVELERS DIARRHEA AND HEPATIC ENCEPHALOPATHY - Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. | 2011-03-17 |
20110065741 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) - The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects. | 2011-03-17 |
20110065742 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high PH environments - Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments. | 2011-03-17 |
20110065744 | Method Of Inhibiting Mucin Secretion - A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin. | 2011-03-17 |
20110065745 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2011-03-17 |
20110065746 | COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID FORMULATION - A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor. | 2011-03-17 |
20110065747 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS - Disclosed are methods of treating a seizure disorder by administering to a patient in need of such treatment a compound having the following formula: | 2011-03-17 |
20110065748 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF GASTROINTESTINAL MOTILITY - Disclosed are methods of treating disorders of gastrointestinal motility by administering to a patient in need of such treatment a compound having the following formula: | 2011-03-17 |
20110065749 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MENTAL DISORDERS - A method of treating a mental disorder including administering to a patient in need thereof, an effective amount of a pharmaceutical composition including 1,1-diphenyl-4-piperidine-1-ylbuthan-1-ol or a pharmaceutically acceptable salt thereof. The mental disorder is depression, bipolar disorder, anxiety disorder, impulsive disorder, bulimia, panic disorder, social anxiety disorder, insomnia, attention deficit hyperactivity disorder (ADHD), schizophrenia, dementia, personality disorder, alcoholism, dissociative disorder, sleep apnea syndrome, or fibromyalgia. In a preferred embodiment, the mental disorder as a therapeutic target is fibromyalgia, chronic fatigue syndrome (CFS), or depression with pain, and the administration of the pharmaceutical composition is capable of reducing the pain caused by these diseases. | 2011-03-17 |
20110065750 | Solid Forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and Methods of Making the Same - The present invention provides for new crystalline and amorphous forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, and methods of making the same. | 2011-03-17 |
20110065751 | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation. | 2011-03-17 |
20110065752 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS - Provided are novel iminosugars and methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Orthomyxoviridae family using iminosugars, such as DNJ derivatives. | 2011-03-17 |
20110065753 | METHODS OF TREATING POXVIRAL INFECTIONS - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives. | 2011-03-17 |
20110065754 | IMINOSUGARS AND METHODS OF TREATING FILOVIRAL DISEASES - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Filoviridae family using iminosugars, such as DNJ derivatives. | 2011-03-17 |
20110065755 | STABLE R(+)-LANSOPRAZOLE AMINE SALT AND A PROCESS FOR PREPARING THE SAME - A stable R-(+)-lansoprazole alkylamine salt and a process for preparing the salt. | 2011-03-17 |
20110065756 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY-RELATED DISEASES - The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and/or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect. | 2011-03-17 |
20110065757 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS - We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma. | 2011-03-17 |
20110065758 | Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions - Methods of diagnosing | 2011-03-17 |
20110065759 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY- )-NICOTINAMIDE AND SALTS THEREOF - The present invention relates to a compound of formula I, | 2011-03-17 |
20110065760 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF - The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z | 2011-03-17 |
20110065761 | METHODS OF TREATING NERVE-RELATED VISION DISORDERS - This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods | 2011-03-17 |
20110065762 | METHODS OF USE OF ANTIVIRAL COMPOUNDS - The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses. | 2011-03-17 |
20110065763 | Compositions for Topical Application Having Androgenic Actions - A composition comprising at least one physiologically tolerated film-forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I | 2011-03-17 |
20110065764 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS - The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders. | 2011-03-17 |
20110065765 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2011-03-17 |
20110065766 | METHODS OF USE OF ANTIVIRAL COMPOUNDS - The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3 protein of Bluetongue). The present invention further relates, inter alia, to compounds which have been shown to possess antiviral activity, in particular, inhibiting the M2 proton channel of influenza viruses. | 2011-03-17 |
20110065767 | Substituted CC-1065 Analogs and Their Conjugates - This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor. | 2011-03-17 |
20110065768 | NON-STEROIDAL ANDROGENS COMPOUNDS - This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula | 2011-03-17 |
20110065769 | Transdermal delivery of ionizable drugs - Provided is a composition for transdermal administration. The composition comprises a therapeutic agent having a net charge at skin pH and a topical penetration enhancer having a net charge at skin pH opposite the net charge of the therapeutic agent. In another aspect, a method is provided for increasing the transdermal absorption of a therapeutic agent. The method comprises forming a therapeutic composition at skin pH by combining a therapeutic agent having a net charge at skin pH with a topical penetration enhancer having a net charge at skin pH opposite the net charge of the therapeutic agent, the ratio of topical penetration enhancer to therapeutic agent being sufficient to increase absorption of therapeutic agent compared to absorption of therapeutic agent in the absence of topical penetration enhancer, and administering the therapeutic composition to a patient in need thereof. | 2011-03-17 |
20110065770 | Formulations comprising antisense nucleotides to connexins - A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening. | 2011-03-17 |
20110065771 | INFLAMMATORY BOWEL DISEASE THERAPIES - The invention relates to methods of treating inflammatory bowel disease in a subject. Methods of promoting intestinal barrier function as well as related compositions are also provided. | 2011-03-17 |
20110065772 | TREATMENT OF RHEUMATOID ARTHRITIS - The present invention provides a method for treating or inhibiting rheumatoid arthritis in a subject, the method comprising administering to the subject a therapeutically effective amount of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or nuclear accumulation or activity of c-Jun protein. | 2011-03-17 |
20110065773 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 2011-03-17 |
20110065774 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF - This invention relates generally to chemically oligonucleotides (e.g., modified oligonucleotides) useful for augmenting activity of a target gene. | 2011-03-17 |
20110065775 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2 - The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. | 2011-03-17 |
20110065776 | Method for Treating Hepatitis C Infection - The present invention relates to a method for treating hepatitis C virus (HCV) infection, comprising administrating a subject in need thereof with a therapeutically effective amount of an inhibitor against a serine/threonine kinase (AKT) and an activator thereof. A method for screening a candidate agent for treating hepatitis C infection determined by the presence of an inhibition of AKT function is also provided. | 2011-03-17 |
20110065777 | DOUBLE-STRANDED RNA (dsRNA) AND METHOD OF USE FOR INHIBITING EXPRESSION OF A FUSION GENE - Specific inhibition of expression of a fusion gene in mammals occurs using a short, double-stranded ribonucleic acid molecule (dsRNA). The dsRNA comprises two separate non-linked RNA strands, an 51 strand and a complementary strand. The strands are 20 to 23 nucleotides in length, and the 51 strand is complementary to the fusion junction of the AML-1/MTG-8 fusion gene. The dsRNA also comprises at least 3 nucleotides on each side of the fusion junction. The dsRNA can be introduced into and maintained in a mammalian cell under conditions and for a time sufficient to obtain degradation of mRNA of the fusion gene to inhibit expression of the fusion gene. The dsRNAs and methods described are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia. | 2011-03-17 |
20110065778 | RNA Interference Mediated Inhibition of Muscarinic Colinergic Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) - The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3). | 2011-03-17 |